EC Number   |
Inhibitors |
Structure |
|---|
   2.7.11.20 | (4-[[4-(1H-benzimidazol-5-ylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzene-1,2-diyl)dicyanamide |
- |
   |
| 2.7.11.20 | 1,1'-(cyclopropane-1,1-diyldisulfonyl)bis(4-chlorobenzene) |
- |
|
| 2.7.11.20 | 1-benzyl-3-cetyl-2-methylimidazolium iodide |
NH125 |
|
| 2.7.11.20 | 1-benzyl-3-cetyl-2-methylimidazolium iodide |
i.e. NH125, inhibits in vitro, but is not a cellular inhibitor elongation factor 2 kinase |
|
| 2.7.11.20 | 1-benzyl-3-cetyl-2-methylimidazolium iodide |
i.e. NH125, inhibits eEF2K activity via inhibition of alpha-kinase, a catalytic domain of eEF2K |
|
| 2.7.11.20 | 1-benzyl-3-cetyl-2-methylimidazolium iodide |
i.e. NH125, inhibits eEF2K activity via inhibition of alpha-kinase, a catalytic domain of eEF2K. In mesenteric artery from spontaneously hypertensive rats, the acetylcholine-induced endothelium-dependent relaxation is significantly impaired after long-term treatment with the inhibitor |
|
| 2.7.11.20 | 1-[3-[(5,6,7-trimethyl-2-phenyl-7H-cyclopenta[d]pyrimidin-4-yl)amino]propyl]pyrrolidin-2-one |
- |
|
| 2.7.11.20 | 2,6-diamino-4-(2-fluorophenyl)-4H-thiopyran-3,5-dicarbonitrile |
- |
|
| 2.7.11.20 | 2-((3,5-di-tert-butyl-4-hydroxyphenyl)-methylene)-4-cyclopentene-1,3-dione |
TX-1123 |
|
| 2.7.11.20 | 2-((3,5-dimethyl-4-hydroxyphenyl)-methylene)-4-cyclopentene-1,3-dione |
TX-1918 |
|
